e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
COPD and asthma pathogenic mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elevation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in healthy smokers
H. Ilumets, P. Rytilä, T. Rehn, A. Sovijärvi, M. Myllärniemi, T. Sorsa, V. Kinnula (Helsinki, Finland)
Source:
Annual Congress 2005 - COPD and asthma pathogenic mechanisms
Session:
COPD and asthma pathogenic mechanisms
Session type:
Thematic Poster Session
Number:
743
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Ilumets, P. Rytilä, T. Rehn, A. Sovijärvi, M. Myllärniemi, T. Sorsa, V. Kinnula (Helsinki, Finland). Elevation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in healthy smokers. Eur Respir J 2005; 26: Suppl. 49, 743
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 651s
Year: 2006
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF
Source: Eur Respir J 2002; 20: 1220-1227
Year: 2002
Metalloproteinase-9 and tissue inhibitor of metalloproteinase in baker‘s asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 603s
Year: 2005
Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 92s
Year: 2002
Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD.
Source: International Congress 2018 – Functional genomics and COPD: new challenges
Year: 2018
Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in pleural effusions
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 54s
Year: 2005
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography
Source: Eur Respir J 2006; 28: Suppl. 50, 745s
Year: 2006
Effects of keratinocyte growth factor (KGF) on matrix metalloproteinases (MMPs) & tissue inhibitors of metalloproteinases (TIMPs) mRNA levels in emphysematous rats lungs
Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD
Year: 2008
Matrix metalloprotease-1 and tissue inhibitor of metalloprotease-1 levels in pleural effusions of different origins
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004
Statins inhibit matrix metalloproteinase release from human lung fibroblasts
Source: Eur Respir J 2010; 35: 637-646
Year: 2010
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension
Source: Eur Respir J 2001; 18: 838-845
Year: 2001
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space
Source: Eur Respir J 2008; 32: 644-650
Year: 2008
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients
Source: Eur Respir J 2005; 25: 885-890
Year: 2005
Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions
Source: Eur Respir J 2005; 25: 104-109
Year: 2005
Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo
Source: Eur Respir J 2002; 20: 170-176
Year: 2002
Imbalance between serum matrix metalloproteinase-9 and its inhibitor is associated with increased airway wall thickness in uncontrolled asthmatics
Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation
Year: 2010
Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17A in mouse airways
Source: Annual Congress 2004 - Insights into asthma and COPD
Year: 2004
Balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the development of bronchiolitis obliterans syndrome after lung transplantation
Source: Eur Respir J 2003; 22: Suppl. 45, 327s
Year: 2003
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept